Dec 15, 2025 7:50 am EST TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone
Dec 8, 2025 7:50 am EST TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition
Nov 14, 2025 7:00 am EST TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Nov 3, 2025 9:01 am EST TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition
Aug 20, 2025 8:00 am EDT TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
Aug 14, 2025 4:15 pm EDT TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Jul 1, 2025 8:50 am EDT TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes